Alembic Pharmaceuticals receives USFDA tentative approval for generic Ribociclib tablets, a breast cancer treatment.

Alembic Pharmaceuticals Ltd has received tentative approval from the USFDA for its generic Ribociclib tablets used in treating breast cancer. The tablets, with a strength of 200 mg, are indicated for adult patients with a certain type of advanced or metastatic breast cancer. The medicine is the generic equivalent of Novartis' Kisqali tablets.